212Pb alpha targeted therapy (Perspective Therapeutics)

N/A

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug Name212Pb alpha targeted therapy (Perspective Therapeutics)
Drug Alias Name[212Pb]-VMT-01[212Pb]VMT-α-NETPb212-VMT-α-NETPb-212-VMT-α-NETLead-212 +[10] 
ClassificationRadiation-emitting products > Radioactive therapeutic agentDiagnostic agent (In vivo)Radiation-emitting products > Nuclides > Lead > 212Pb +[5] 
Mechanisms of ActionMelanocortin receptor 1 bindersIonising radiation emitters
TargetsMelanocortin receptor 1
Therapy Area/IndicationsGastroenteropancreatic neuroendocrine tumorSmall Cell Lung CarcinomaLung Neoplasms +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPerspective Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesPerspective Therapeutics IncLantheus Holdings IncNational Cancer Institute
Inactive CompaniesN/A
Active IndicationsGastroenteropancreatic neuroendocrine tumorSmall Cell Lung CarcinomaLung Neoplasms +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A